menu search

BSX / Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?

Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies. Read More
Posted: Jan 20 2023, 09:47
Author Name: Zacks Investment Research
Views: 110113

BSX News  

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

By Zacks Investment Research
October 26, 2023

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter. more_horizontal

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

By Zacks Investment Research
October 26, 2023

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

Boston Scientific (BSX) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to more_horizontal

Boston Scientific posts better-than-expected Q3 earnings

By Market Watch
October 26, 2023

Boston Scientific posts better-than-expected Q3 earnings

Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical t more_horizontal

Boston Scientific beats quarterly profit estimates on strength in heart devices unit

By Reuters
October 26, 2023

Boston Scientific beats quarterly profit estimates on strength in heart devices unit

Medical device maker Boston Scientific topped Wall Street expectations for third-quarter profit on Thursday, helped by a resilient demand for its hear more_horizontal

Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery

By Reuters
October 25, 2023

Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery

Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the med more_horizontal

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

By Zacks Investment Research
October 23, 2023

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improve more_horizontal

The Pros Got It Wrong: 3 Stocks to Sell Despite Recent Upgrades

By InvestorPlace
October 18, 2023

The Pros Got It Wrong: 3 Stocks to Sell Despite Recent Upgrades

One tool that investors can easily access for any stock is analyst ratings. These ratings point you in the direction of stocks to buy and stocks to se more_horizontal

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

By Zacks Investment Research
October 16, 2023

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems. more_horizontal


Search within

Pages Search Results: